Charlotte Pawlyn
Institute of Cancer Research, United Kingdom
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Charlotte Pawlyn as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:06 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07649525 · Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelUniversity of Leeds · recruiting · Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:06 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.J Clin Oncol · 2015472 citationsRCR 12.9
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2019309 citationsRCR 11.7
- A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.Lancet Haematol · 2019103 citationsRCR 4.4
- Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 202395 citationsRCR 7.8
- 93 citationsRCR 4.2
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.N Engl J Med · 202685 citationsRCR 42.5
- The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.Clin Cancer Res · 201679 citationsRCR 2.2
- 79 citationsRCR 3.9
- 76 citationsRCR 2.7
- Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.Blood Cancer J · 201671 citationsRCR 2.2